Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline (2021) Gorski M, Jung B, Li Y, Matias-Garcia PR, Wuttke M, Coassin S, Thio CH, et al. Journal article Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, et al. Journal article, Review article KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) (2020) Dent R, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, et al. Journal article Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, et al. Journal article, Review article Pembrolizumab for early triple-negative breast cancer (2020) Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution